Products of other enterprises
Technical characteristics
- BrandCare
Description
Worldwide, 250 million people are currently living with diabetes, and this population will grow to 380 million before 2025. Building upon its century long history in this field, Sanofi is committed to improving global diabetes management through its integrated offering of treatments, medical devises and services.
Medicines
Our principle medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS sales 2010).
Apidra® (insulin glulisine) a rapid-acting human insulin analog.
Insuman®, a range of rapid- and intermediate-acting human insulins.
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic.
Medicines
Our principle medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS sales 2010).
Apidra® (insulin glulisine) a rapid-acting human insulin analog.
Insuman®, a range of rapid- and intermediate-acting human insulins.
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic.
Contact the seller
Diabetes care
We recommend to see